Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

The invention relates to methods for treating subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria, using iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and anti-C5 antibodies, e.g., eculizumab.

Medicaments for the treatment of sexual disorder

生理活性糖蛋白質及びその製造方法

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Pharmacological composition for treating urolith

USE OF GALLOPAMIL FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF ACUTE KIDNEY FAILURE

Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure

내용 없음 No content

Novel method for producing 17β alkanoyl 3-oxo-4-aza-5α-androst-1-enes

Patent JPH0476970B2

Bladder nuclear matrix protein and its use in the detection and treatment of cell proliferative disorders

(57)【要約】 膀胱組織での明確な発現を特徴とする核マトリックスタンパク質（ＮＭＰ）を提供する。このＮＭＰは、膀胱の悪性疾患の病期診断およびモニタリングおよび膀胱の細胞増殖性疾患の治療に有用なマーカーである。実質的に精製された、本発明のポリペプチドおよび本発明のＮＭＰをコードしているポリヌクレオチド配列も提供する。

Pharmaceutical composition

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

USE OF ALFUZOSINE FOR THE PREPARATION OF MEDICINAL PRODUCTS

PHARMACEUTICAL COMPOSITIONS CONTAINING A MIXTURE OF SALTS OF CETOACIDS AND AMINO ACIDS USEFUL FOR THE TREATMENT OF UREMIA

NOVEL ARYLPIPERIDINIC DERIVATIVE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.

Compositions and methods for treating benign prostatic hypertrophy.

PHARMACEUTICAL COMPOSITIONS CONTAINING A MIXTURE OF SALTS OF CETOACIDS AND AMINO ACIDS USEFUL FOR THE TREATMENT OF UREMIA

Compositions pharmaceutiques contenant un mélange de cinq sels formés par des alpha-céto-acides et des acides aminés basiques et de la L-tyrosine, de la L-thréonine, du L-tryptophane et du D, L-alpha-hydroxy-gamma-méthyl-thio-butyrate de calcium. Pharmaceutical compositions containing a mixture of five salts formed by alpha-keto acids and basic amino acids and L-tyrosine, L-threonine, L-tryptophan and D, L-alpha-hydroxy-gamma- calcium methyl thio-butyrate.

APPLICATION OF ACYL-CARNITINES TO A THERAPEUTIC PROCESS FOR THE TREATMENT OF CHRONIC UEMIC PATIENTS IN PERIODIC HEMODIALYTIC TREATMENT AND LIQUID COMPOSITION OF DIALYSIS FOR THE IMPLEMENTATION OF SUCH A PROCESS

Procédé thérapeutique pour traiter des patients urémiques chroniques en traitement hémodialytique périodique, caractérisé en ce qu'il consiste à administrer par voie orale à de tels patients tant les jours du traitement hémodialityque que les jours compris entre un traitement hémodialytique et le suivant, de 3 à 6 g par jour d'une acyl-carnitine de formule générale : Therapeutic process for treating chronic uremic patients undergoing periodic hemodialytic treatment, characterized in that it consists in administering orally to such patients both on the days of the hemodialytic treatment and on the days between one hemodialytic treatment and the next, from 3 to 6 g per day of an acyl-carnitine of general formula:

HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENT CONTAINING THEM

L'invention a pour objet de nouveaux dérivés d'acide hydroxamique de formule : R1 - CONHCH2 CONHOH (dans laquelle R1 est un groupe alkyle de 4 à 11 atomes de carbone) et les sels pharmacologiquement acceptables de ces dérivés. Ces dérivés sont utilisables pour le traitement de l'urolithiase et de la pyélonéphrite. The subject of the invention is new hydroxamic acid derivatives of formula: R1 - CONHCH2 CONHOH (in which R1 is an alkyl group of 4 to 11 carbon atoms) and the pharmacologically acceptable salts of these derivatives. These derivatives can be used for the treatment of urolithiasis and pyelonephritis.

PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF UREMIA

7 (ALPHA) -ALKYL-17 (ALPHA) -PREGN-4-EN-21.17-CARBOLACTONE AND -21-CARBONIC ACID SALTS AND METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM

Patent FR2425854B1

Topical preparations containing danazol

Abstract: TOPICAL PREPARATIONS CONTAINING DANAZOL A topical preparation of danazol comprising a matrix base, danazol retained therein, and optionally a release-promoting agent is provided. The topical preparation is more effective than oral administration of danazol in the shrinkage of endometriosis tissue, the induction of pregnancy, and the like. It does not show any side effects that have been encountered in the oral administration of danazol. Thus, the preparation is very useful remedy for endometriosis.

PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF UREMIA

Compositions pharmaceutiques, contenant un mélange de plusieurs sels d'acides alpha-aminés basiques et d'alpha-céto-analogues d'acides aminés essentiels à chaîne ramifiée, caractérisées par le fait qu'elles sont présentées sous forme de comprimé enrobé gastrorésistant ou gastrosoluble. Pharmaceutical compositions, containing a mixture of several salts of basic alpha-amino acids and alpha-keto-analogs of essential amino acids with branched chain, characterized in that they are presented in the form of a coated gastro-resistant or gastrosoluble tablet .

Patent FR2436134B1

New arylpiperidine derivative, process for its preparation and pharmaceutical compositions containing it.

L'invention a pour objet la 1-[2-(2-naphtyl)éthyl]-4-(3-trifluorométhylphényl)pipéridine et ses sels d'addition d'acides, utiles dans le traitement du dysfonctionnement sexuel chez les mammifères. Le nouveau composé peut être préparé par exemple par hydrogénation catalytique du correspondant dérivé 1,2,3,6-tétrahydropyridinique. The subject of the invention is 1- [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) piperidine and its acid addition salts, useful in the treatment of sexual dysfunction in mammals. The new compound can be prepared, for example, by catalytic hydrogenation of the corresponding 1,2,3,6-tetrahydropyridine derivative.

Method of treating premature ejaculation using sertraline

Abstract Disclosed is a medicine for treating premature ejaculation of a human in need of such treatment. The medicine comprises an amount of the compound (lS-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-l-naphthalenamine, also known by the generic name sertraline, or a pharmaceutically acceptable salt thereof, effective in delaying ejaculation, together with a pharmaceutically acceptable carrier.

Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl) ethylamino)pyrimidine trihydrochloride as active ingredient

Remedy for renal disease

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Treatment of endometriosis

Disclosed is a use of danazol for vaginal administration in a form of powder, tablet, suppository, capsule or liquid, or for parenteral and non-vaginal administration in a form of a solution, the content or concentration of danazol is specified.

Treatment of diabetic nephropathy with valsartan

The angiotensin II antagonist of formula (I) and the pharmaceu-tically acceptable salts thereof can be used for the therapeutic treat-ment of diabetic nephropathy.

A pharmaceutical composition containing a pyrazolopyrimidinone compound for preventing and treating prostate enlargement

N-imidazolyl derivatives of bicyclic compounds useful in medicine

A B S T R A C T N-Imidazolyl Derivatives of Bicyclic Compounds useful in medicine. The invention relates to the use of a compound of formula (I) (I) wherein (a) is wherein Y completes a single bond or is oxygen or a -CH2- group and the symbol represents a single or a double bond or (b) is and the symbol represents a double bond; one of R1, R2, R3 and R4 is -CH2OH, C2-C4 acyl, , -COOR7, -CH2-COOR7, , -CH-?-COOR? or

Trophinin and trophinin-assisting proteins

The present invention provides substantially purified mammalian trophinin which can mediate cell adhesion. The invention also provides substantially purified trophinin-assisting proteins, which interact with trophinin to mediate cell adhesion. The invention further provides antibodies that are specifically reactive with trophinin or a trophinin-assisting protein. In addition, the invention provides active fragments of trophinin or trophininassisting proteins. The invention further provides a nucleic acid molecule encoding trophinin or a trophinin-assisting protein, vectors containing the nucleic acid molecules and host cells containing the vectors. The invention also provides a nucleotide sequence that can hybridize to a nucleic acid molecule encoding trophinin or a trophinin-assisting protein. The invention further provides methods to detect trophinin or a trophinin-assisting protein or a nucleic acid molecule encoding trophinin or a trophinin-assisting protein in a sample. The invention also provides methods of effecting cell adhesion by modifying cells to express trophinin or a trophinin-assisting protein. The invention further provides trophinin antagonists and methods to reduce or inhibit cell adhesion. The invention also provides methods to treat cells with trophinin agonists to increase cell adhesion.

Process for the production of medical preparations containing 10-amino-5,6-dihydro-11h-dibenzo/b,e/azepin-6,11-dion and its derivatives

New process for making 17-beta alkanoyl 3-oxo-4-aza-5-alpha-androst-1-enes

Iminopyridine derivatives and use thereof

The present invention aims to provide an iminopyridine derivative compound having an .alpha.1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like.The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Nephrological-urological medicine

ABSTRACT NEPHROLOGICAL-UROLOGICAL MEDICINE L-cysteine and its pharmacologically compatible acid addition salts is used for combating phosphatic calculi produces fewer side effects and can be administered in smaller effective doses than previously employed medications such as L-methionine and ascorbic acid.

Trophinin and trophinin-assisting nucleic acids and methods of detection thereof

The present invention provides substantially purified mammalian trophinin which can mediate cell adhesion. The invention also provides substantially purified trophinin-assisting proteins, which interact with trophinin to mediate cell adhesion. The invention further provides antibodies that are specifically reactive with trophinin or a trophinin-assisting protein. In addition, the invention provides active fragments of trophinin or trophinin-assisting proteins. The invention further provides a nucleic acid molecule encoding trophinin or a trophinin-assisting protein, vectors containing the nucleic acid molecules and host cells containing the vectors. The invention also provides a nucleotide sequence that can hybridize to a nucleic acid molecule encoding trophinin or a trophinin-assisting protein. The invention further provides methods to detect trophinin or a trophinin-assisting protein or a nucleic acid molecule encoding trophinin or a trophinin-assisting protein in a sample. The invention also provides methods of effecting cell adhesion by modifying cells to express trophinin or a trophinin-assisting protein. The invention further provides trophinin antagonists and methods to reduce or inhibit cell adhesion. The invention also provides methods to treat cells with trophinin agonists resulting in increased cell adhesion.

Method for producing new aryl-piperidine derivatives and pharmaceutical preparatives containing them

Dialysis fluid

Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure

Iminopyridine derivative and use thereof

The present invention aims to provide a compound having a superior selective .alpha.1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula (I) (see formula I) wherein each symbol is as defined in the specification, or a salt thereof.

USE OF A DERIVATIVE OF 3-HYDROXIBUTANOIC ACID.

EL INVENTO ES UNA SOLUCION PARA LA DIALISIS QUE CONTIENE UN DERIVADO DEL ACIDO 3 - HIDROXIBUTANOICO ELEGIDO ENTRE LOS OLIGOMEROS DE ESTE ACIDO Y LOS ESTERES DE ESTE ACIDO O DE ESTOS OLIGOMEROS CON EL 1,3 - BUTANODIOL THE INVENTION IS A SOLUTION FOR DIALYSIS CONTAINING A DERIVATIVE OF ACID 3 - HYDROXIBUTANOIC CHOSEN BETWEEN THE OLIGOMERS OF THIS ACID AND THE ESTERS OF THIS ACID OR THESE OLIGOMERS WITH 1,3 - BUTANODIOL

PHOSPHORAMIDE DERIVATIVES, PROCEDURE FOR THE PREPARATION OF THESE AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF URINARY STONES AND PYELONEFRIT FREE CAUSED BY A URINAL INFECTION OF UREA-PRODUCING BACTERIA

Use of sertraline for the treatment of premature ejaculation

Method of treating recurrent miscarriage and improving the efficacy of assisted reproductive techniques using placental protein 14

ABSTRACT OF THE DISCLOSURE A method of preventing miscarriage in a female by administering to the female a therapeutically effective amount of an active substance selected from the group consisting of PP14, derivatives of PP14, muteins of PP14, fragments of PP14, and subunits of PP14, so as to prevent miscarriage. A method of testing a female for the possibility of future miscarriage by measuring the level of PP14 in the female, and comparing the measured level to the level of PP14 present in normal fertile women. A method of improving the efficacy of assisted reproductive techniques such as artificial insemination, in-vitro fertilization, or gamete intra-fallopian transfer, by adding an effective amount of PP14 to a sample comprising an embryo, fertilized or unfertilized egg, mixture of eggs and sperm, or sperm alone, prior to, concurrently with, or following introduction of the sample into the patient.

New process for making 17-beta alkanoyl 3-oxo-4-aza-5-alpha-androst-1-enes

Disclosed is a new process for making 17-beta branched alkanoyl-3-oxo-4-aza-5-α-androst-1-enes, agents for treating benign prostatic hypertrophy (BPH), by reacting methyl 3-oxo-4-aza-5-α-androst-1-ene-17-beta carboxylate with isobutylmagnesium bromide in the novel presence of hexamethyldisilazane (HMDS). Use of the HMDS results in higher yield and less by-products as opposed to the standard Grignard reaction in the absence of HMDS.

Novel therapeutic carbohydrate blends useful for aiding premenstrual syndrome

Novel therapeutic compositions comprising carbohydrate blends and methods of using the compositions for the treatment of premenstrual syndrome (PMS).

Ancrod-like proteins, their preparation and use

Process for making 17-.beta. alkanoyl 3-oxo-4-aza-5-alpha-androst- 1-enes

TITLE OF THE INVENTION ABSTRACT OF THE DISCLOSURE Disclosed is a new process for making 17-beta branched alkanoyl-3-oxo-4-aza-5-.alpha.-androst-1-enes, agents for treating benign prostatic hypertrophy (BPH), by reacting methyl 3-oxs-4-aza-5-.alpha.-antrost-l-ene-17-beta carboxylate with isobutylmagnesium bromide in the novel presence of hexamethyldisilazane (HMDS). Use of the EMDS results in higher yield and less by-products as opposed to the standard Grignard reaction in the absence of HMDS.

MEDICINALLY EASY N-IMIDAZOLYL DERIVATIVES OF BICYCLIC COMPOUNDS

PAF-antagonists as medicaments for the treatment of dysmenorrhea

The invention relates to the use of 4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-1-yl]-6H- thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine and 6-(2-chlorphenyl)-8,9-dihydro-1-methyl-8-[(4-morpholinyl)carbonyl]-4H, 7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine for the treatment of dysmenorrhoea, especially primary dysmenorrhoea.

Treatment of endometriosis

Disclosed is a use of danazol for vaginal administration in a form of powder, tablet, suppository, capsule or liquid, or for parenteral and non-vaginal administration in a form of a solution, the content or concentration of danazol is specified.

compound, prodrug, pharmaceutical agent, method for prophylaxis or treatment of lower urinary tract diseases in a mammal, and use of a compound or a prodrug thereof.

Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders

Nuclear matrix proteins (NMPs) which are characterized by a defined expression in bladder tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy, and treating cell proliferative disorders of the bladder. Also provided are substantially purified polypeptides and polypeptide sequences encoding the NMPs of the invention.

Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules

Methods, including culture media conditions, which provide for isolation and purification of renal tubule stem cells and for in vitro kidney tubulogenesis are disclosed. The methods rely on culturing adult kidney cells in a culture media treated with combinations of transforming growth factor-β 1 , epidermal growth factor, and all-trans retinoic acid.

IMINOPIRIDINE DERIVATIVES AND USE OF THE SAME

Se describe un compuesto el cual tiene una excelente actividad selectiva superior como antagonista del receptor adrenérgico 1D y por lo tanto es útil como un agente profiláctico/terapéutico para el tratamiento de una enfermedad del tracto urinario inferior y similares. Se describe específicamente un compuesto representado por la fórmula (I) [en donde cada símbolo es como se definió en la descripción] o una de sus sales.

PHARMACEUTICAL COMPOSITIONS CONTAINING ALFUZOSINE

PHARMACEUTICAL AND DIETARY COMPOSITION CONTAINING .alpha.-LINOLENIC ACID

PHARMACEUTICAL AND DIETARY COMPOSITIONS ABSTRACT The preparation of a composition for the treatment of benign prostatic hypertrophy wherein .gamma.-linolenic acid or dihomo-.gamma.-linolenic acid or both, as such or in the form of acceptable and physiologically equivalent derivatives, are brought into administrable form, optionally with a carrier or diluent.

PHOSPHORAMIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION

Agent for the prevention and treatment of prostatic hyperplasia comprising a pyrazolopyrimidinone compound

14,17 beta-ethano-14 beta-estratrienes and estratetraenes processes for their production and pharmaceutical preparations containing them

Compositions and methods for treating benign prostatic hypertrophy

Invented are pharmaceutical compositions containing N-t-butyl-androst-3,5-diene-17β-carboxamide)-3-carboxylic acid or a salt thereof or 17β-(N-t-butylcarboxamide-estra-1,3,5(10)-triene-3-carboxylic acid or a salt thereof and an alpha-adrenergic receptor antagonist compound, and methods of using these compositions to treat benign prostatic hypertrophy.

Drug for recovering renal function

Drug which contains human growth hormones capable of recovering the renal function when administered to a patient who has renal insufficiency but has not yet undergone kidney dialysis. By administrating the drug, the loss of renal function represented by an extreme decrease in creatinine clearance or the reciprocal of blood creatinine level can be prevented and thus it can dispense with the dialytic treatment for patients with renal insufficiency.

PROCEDURE FOR PREPARING 2-CYANOSTEROIDS.

Pharmaceutical

Use of a 10-amino-5,6-dihydro-11H-dibenzo(b,e)azepine-6,11-dione of formula I where R represents an atom of hydrogen or a lower alkyl group, especially containing from 1 to 5 carbon atoms, as well as of a therapeutically acceptable salt of said compound, to prepare a drug for use in the treatment of urinary incontinence.

PHOSPHORAMIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION

LA PRESENTE INVNETION EST RELATIVE A DES DERIVES DE PHOSPHORAMIDE UTILISABLES NOTAMMENT POUR LE TRAITEMENT DES LITHIASES URETRALES ET DES PYELONEPHRITES, REPONDANT A LA FORMULE GENERALE: (CF DESSIN DANS BOPI) DANS LAQUELLE X ET Y REPRESENTENT CHACUN UN ATOME D'HYDROGENE OU X ET Y FORMENT ENSEMBLE UNE DOUBLE LIAISON ENTRE LES DEUX ATOMES DE CARBONE ADJACENTS SUR LESQUELS ILS SONT RESPECTIVEMENT FIXES, ET N REPRESENTE UN NOMBRE ENTIER DE 0 A 2. THE PRESENT INVNETION IS RELATING TO PHOSPHORAMIDE DERIVATIVES USED IN PARTICULAR FOR THE TREATMENT OF URETRAL LITHIASES AND PYELONEPHRITES, RESPONDING TO THE GENERAL FORMULA: (CF DRAWING IN BOPI) IN WHICH X AND EACH YROGOME AND XYD-OR XYD REPRESENT A YROGOME OR XYD TOGETHER FORM A DOUBLE BOND BETWEEN THE TWO ADJACENT CARBON ATOMS ON WHICH THEY ARE RESPECTIVELY FIXED, AND N REPRESENTS A WHOLE NUMBER FROM 0 TO 2.

Method and compositions of a bioartificial kidney suitable for use in vivo or ex vivo

A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Renal cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure as well as studying renal tubululogenesis in vitro.

Novel 18-phenyloestrane derivatives

Mammalian reproductive function. Drugs to improve

14,17-G(B)-ETHANO-14-G(B)-ESTRATRIENE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.

14,17 beta -ethano-14 beta -estratriene and estratetraene of Formula I <IMAGE> (I) wherein R1 is a hydrogen atom, a methyl or an acyl group of a monocarboxyclic acid of 1-12 carbon atoms, R2 is a hydrogen atom or an acyl group of a monocarboxylic acid of 1-12 carbon atoms, R3 is a hydrogen atom or a methyl group, and <IMAGE> is a single or double C-C-bond show strong estrogenic activity.

A pyrazolopyrimidinone derivative for the prevention and treatment of prostatic hyperplasia

The disclosure relates to the use of a compound of formula (1) as an agent for preventing and treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH and a relaxant for relaxing urethral smooth muscle or prostatic smooth muscle comprising a pyrazolopyrimidinone compound as an effective ingredient. Said agent can provide nitric oxides by inhibiting the activity of PDE-5 that decomposes c-GMP, and the provided nitric oxides relax the urethral smooth muscle or the prostatic smooth muscle to lower the intraurethral pressure (IUP), thus treating BPH and LUTS associated with BPH. Furthermore, the time required for reaching a maximum blood concentration is shorter and the half-life is longer than the other PDE-5 inhibitors, thus reducing the frequency of administration. Moreover, the agent causing few side effects can be efficiently used as a safe drug.

Process for production of pharmaceutical composition containing sertraline for treatment of premature ejaculation

Use of gallopamil for producing drugs for treating acute renal failure

- 6 - O.Z. 0480/01080 Abstract of the Disclosure: Gallopamil and salts thereof with physiologically tolerated acids are used for produc-ing drugs for treating acute renal failure.

Medicines to treat vulvar dystrophy or vaginal dryness

Fatty acid treatment

ABSTRACT Gamma-linolenic (GLA) and/or dihomo-gamma-linolenic acid (DGLA) may be used in the treatment of vulvar dystrophy and/or vaginal dryness. Other essential fatty acids of the n-6 or n-3 series may also be used in association with GLA and/or DGLA.

Use of pinacidil in the treatment of incontinence

A method for the treatment and/or prophylaxis of incontinence in mammals, which method comprises administering to the mammal an effective amount of the compound pinacidil or a pharmaceutically acceptable salt or solvate thereof.

New 18-phenyl estrane derivative

本发明公开了一组新的甾族化合物，它们具有中止妊娠和/或避孕活性，并具有很低的抗糖皮质激素活性，此类化合物通式为：(I) 其中R 1 和R 2 分别表示氢原子或1—4个碳的烃基，或者R 1 和R 2 一起表示2—6个碳的烃基；R 3 表示氢原子或1—4个碳的烃基，并可带有选择性的羟基；R 4 表示羟基、酯基或醚基，或者与R 3 一起表示氧或含氧杂环；图中的虚线表示甾族化合物骨架位置9和10的碳原子之间有一可选择的双键。这些化合物的制备方法以及以它们作为活性物质的药物组合物也在专利申请之内。

Iminopyridine derivatives and use thereof

Use of bucillamine in the manufacture of a medicament for the treatment of cystinuria.

N-imidazolyl derivatives of pharmaceutical bicyclic compounds

내용 없음

Cell volume-regulated human kinase h-sgk

The present invention relates to the cloning and characterization of a human serine/threonine kinase (h-sgk: serum and glucocorticoid dependent kinase). The invention furthermore relates to reagents for diagnosing conditions associated with a change in cell volume and/or in "macromolecular crowding" in the body, such as, for example, hypernatremia, hyponatremia, diabetes mellitus, renal failure, hypercatabolism, hepatic encephalopathy, inflammation and microbial or viral infections. The present invention additionally relates to pharmaceuticals comprising the h-sgk, nucleic acids which code for the h-sgk, or receptors, in particular antibodies, which specifically bind to the h-sgk.

Growing renal tubule cells and ex vivo renal tubule tissue system

Treating renal failure by passing blood from a patient through a blood filtering device and passing the filtrate obtained through a tubule processing device. Also disclosed is a method of growing tubule cells ex vivo by culturing adult kidney cells in a three dimensional collagen gel in the presence of retinoic acid and epidermal growth factor to achieve tubulogenesis, and the ex vivo renal tubule tissue system obtained therefrom.

2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES

PROCESS FOR THE PREPARATION OF A NEW MEDICAMENT FROM ALPHA, ALPHA-DIPHENYL-ALPHA-ALKOXY ACETIC ACID 1-METHYLPIPERIDYL-4-ESTER DERIVATIVES

Compositions and methods for treating benign prostatic hypertrophy

Invented are pharmaceutical compositions containing N-t-butyl-androst-3,5-diene-17.beta.-carboxamide)-3-carboxylic acid or a salt thereof or 17.beta.-(N-t-butylcarboxamide-estra-1,3,5(10)-triene-3-carboxylic acid or a salt thereof and an alpha-adrenergic receptor antagonist compound, and methods of using these compositions to treat benign prostatic hypertrophy.

Nephritis treating agent

The agent contains N-2'-carboxyl-3',6'-dimethylphenyl-4-chloroanthranilic acid or a salt thereof as active ingredient.

N-imidazolyl derivatives for treating nephropathies

Compounds of formula: <IMAGE> where <IMAGE> wherein Y completes a single bond or is oxygen or a -CH2-group and --- is a single or a double bond or (b> <IMAGE> and --- is a double bond; one of R1, R2, R3 and R4 is -CH2OH, C2-C4 acyl, <IMAGE> in which each each of R7, R8 and R9 is hydrogen or C1-C4 alkyl and the others are chosen from hydrogen, hydroxy, halogen, C1-C4 alkyl, C1C4 alkoxy and -COOR7 wherein R7 is as above, and one of R5 and R6 is hydrogen and the other is hydrogen, C1-C6 alkyl or phenyl; or a pharmaceutically acceptable salt thereof are used to treat nephropathies.

Vitamin D compounds with anti-progesterone activity

A birth control method for a female mammal which comprises administering to the mammal an amount of a vitamin D compound sufficient to block binding of progesterone to the progesterone receptor in said mammal.

7alpha-alkyl-17alpha-pregn-4-ene-21,17- carbolactone and -21-carboxylate, manufacture and antialdosteronic pharmaceutic-al medicine

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Bladder nuclear matrix proteins and their use in detecting and treating cell proliferative disorders

Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound

Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2- 2- 4-(2-methoxyphenyl)piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient

A sustained-release formulation of 5-acetyl-4,6-dimethyl-2-Ä2-Ä4-(2-methoxyphenyl)piperazinylÜethylaminoÜ pyrimidine trihydrochloride coated with a release-controlling film comprising a water-insoluble polymer film having no hydrophilic group. The formulation of the present invention has such a release pattern that the drug release lasts for 20 hours or more, so that can be appropriately administered for treatment. Furthermore, the formulation itself is so stable that its release pattern does not change with pH and the formulation does not suffer from deterioration, coloration and the like with the lapse of time.

METHOD FOR INHIBITION OF FOLICULAR MATURATION.

A method is provided for inhibiting the maturation of follicles in the ovary of a femal mammal comprising administering to the ovary of the mammal an effective amount of activin. This method is particularly effective in treating polycystic ovarian disease.

Methods and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules

Methods, including culture media conditions, which provide for isolation and purification of renal tubule stem cells and for in vitro) kidney tubulogenesis are disclosed. The methods rely on culturing adult kidney cells in a culture media treated with combinations of transforming growth factor-.beta.1, epidermal growth factor, and all-trans retinoic acid.

OXYTOCIN AND ANTI-DAYS FOR THE INTRODUCTION OF BIRTH OR ON THE THERAPEUTIC STOP OF GRAVIDITY

A combination product contains oxytocin and/or an oxytocin analog and an antigestagen for induction of birth.

Fatty acid treatment

Chemotactic factors for human spermatozoa and their use in human assisted fertilization

The invention relates to chemotactic factors for human spermatozoa that are purifiable from human follicular fluid. The factors are of peptidic and hydrophilic nature. The first factor has a molecular size of about 13 kDa and, the other, an apparent molecular size smaller that 1.3 kDa, as determined by high pressure gel filtration, as shown in the figure. They are for use in procedures related to human fertilization, particularly artificial insemination, in vitro fertilization, micromanipulation and direct microinjection of sperm to oocytes.

Use of tyrosine for improving the fertility of mammals.

The fertility of female mammals can be improved by dispensing once or within a short time repeatedly a high dosage of tyrosine. The dispensation can be carried out at will intravenously or orally.